CHEMILUMINISCENT IMMUNOASSAYS SHOULD NOT BE USED TO MEASURE SERUM TESTOSTERONE IN PROSTATE CANCER PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II1 Apr 2018PD14-04 CHEMILUMINISCENT IMMUNOASSAYS SHOULD NOT BE USED TO MEASURE SERUM TESTOSTERONE IN PROSTATE CANCER PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY Mercé Cuadras, Enric Miret, Ricardo López, Imma Comas, Roser Ferrer, Jacques Planas, Ana Celma, Xavier Maldonado, Joan Carles, Lucas Regis, and Juan Morote Mercé CuadrasMercé Cuadras More articles by this author , Enric MiretEnric Miret More articles by this author , Ricardo LópezRicardo López More articles by this author , Imma ComasImma Comas More articles by this author , Roser FerrerRoser Ferrer More articles by this author , Jacques PlanasJacques Planas More articles by this author , Ana CelmaAna Celma More articles by this author , Xavier MaldonadoXavier Maldonado More articles by this author , Joan CarlesJoan Carles More articles by this author , Lucas RegisLucas Regis More articles by this author , and Juan MoroteJuan Morote More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.790AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Serum testosterone (ST) measurement is recommended in prostate cancer (PCa) patients undergoing androgen deprivation therapy (ADT) to assess its efficacy and to diagnose castration resistance (CR). ST up to 50 ng/dL is a strong criteria to define CR. Although liquid chromatography and tandem mass espectrometry (LC-MSMS) is the appropriate method, chemiluminiscent immunoassays (CLIAs) are widely used in spite of their lack of accuracy and reproducibility, given that they are automatable, fast, sensitive and inexpensive. Our objective here is to release that the information provided by the measurement of ST with CLIAs is misleading and can lead to wrong decisions. METHODS ST was measured in 143 PCa patients undergoing luteinizing hormone-releasing hormone (LH-RH) agonist with LC-MSMS (Agilent Inc), Advia-Centaur CLIA (Siemens Inc) and Cobas 8000 CLIA (Roche Inc). Behaviour of ST according to the method is analysed, especially the rate of levels behind 50 ng/dL. RESULTS Median ST (range) was 15.0 ng/dL (2-102) with LC-MSMS, 32.3 ng/dL (10-91.6) with AC-CLIA, p <0.001, and 10.3 ng/dL (2.5-54.6) with Cobas-CLIA, p <0.001. ST with LC-MSMS was below 20 ng/dL in 87 patients (60.8%), between 20 and 50 ng/dL in 48 (33.6%) and behind 50 ng/dL in 8 (5.6%). The rate of patients having ST behind 50 ng/dL with the AC-CLIA was in 18.2%, while it was 1.4% with the Cobas-CLIA, p <0.001. CONCLUSIONS CLIAs are not accurate to measure ST in PCa patients undergoing LH-RH agonist. They can overestimate and underestimate the true levels of ST measured with LC-MSMS. Because ST up to 50 ng/dl is a strong criteria to define CR, wrong clinical decisions can be made based on the measurement of ST with inappropriate methods. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e306 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Mercé Cuadras More articles by this author Enric Miret More articles by this author Ricardo López More articles by this author Imma Comas More articles by this author Roser Ferrer More articles by this author Jacques Planas More articles by this author Ana Celma More articles by this author Xavier Maldonado More articles by this author Joan Carles More articles by this author Lucas Regis More articles by this author Juan Morote More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...